Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2024 Feb 19

PMID 38372871

Authors

Wang-Chun Ho

Chung-Chih Chang

Wen-Tien Wu

Ru-Ping Lee

Ting-Kuo Yao

Cheng-Huan Peng

Kuang-Ting Yeh

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The purpose of this literature review was to determine if medications used to treat osteoporosis are also effective for treating osteoarthritis (OA).

Recent Findings: A total of 40 relevant articles were identified. Studies were categorized into those (1) discussing estrogen and selective estrogen receptor modulators (SERMs), (2) bisphosphonates, (3) parathyroid hormone (PTH) analogs, and (4) denosumab, and (5) prior review articles. A large amount of evidence suggests that estrogen and SERMs are effective at reducing OA symptoms and disease progression. Evidence suggests that bisphosphonates, the most common medications used to treat osteoporosis, can reduce OA symptoms and disease progression. In vivo studies suggest that PTH analogs may improve the cartilage destruction associated with OA; however, few human trials have examined its use for OA. Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been done with respect to its effect on OA. The current evidence indicates that medications used to treat osteoporosis are also effective for treating OA. Estrogen, SERMs, and bisphosphonates have the most potential as OA therapies. Less is known regarding the effectiveness of PTH analogs and denosumab in OA, and more research is needed.

Citing Articles

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study.

Yu T, Wu W, Lee R, Chen I, Wang J, Wen S Life (Basel). 2025; 14(12.

PMID: 39768410 PMC: 11677198. DOI: 10.3390/life14121704.

The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies.

Di Cicco G, Marzano E, Mastrostefano A, Pitocco D, Castilho R, Zambelli R Biomedicines. 2024; 12(10).

PMID: 39457605 PMC: 11505501. DOI: 10.3390/biomedicines12102292.

Connecting the dots: sex, depression, and musculoskeletal health.

Newman M, Donahue H, Neigh G J Clin Invest. 2024; 134(18).

PMID: 39286983 PMC: 11405046. DOI: 10.1172/JCI180072.

Multi-omics Analysis to Identify Key Immune Genes for Osteoporosis based on Machine Learning and Single-cell Analysis.

Zhang B, Pei Z, Tian A, He W, Sun C, Hao T Orthop Surg. 2024; 16(11):2803-2820.

PMID: 39238187 PMC: 11541141. DOI: 10.1111/os.14172.

S-Equol Ameliorates Menopausal Osteoarthritis in Rats through Reducing Oxidative Stress and Cartilage Degradation.

Hu Y, Huang T, Huang L, Cheng H, Hsieh B, Chang K Nutrients. 2024; 16(14).

PMID: 39064807 PMC: 11280421. DOI: 10.3390/nu16142364.

References

Huang K, Wu B, Hou Z, Ahmad A, Ahmed M, Khan A . Psoralen downregulates osteoarthritis chondrocyte inflammation via an estrogen-like effect and attenuates osteoarthritis. Aging (Albany NY). 2022; 14(16):6716-6726. PMC: 9467404. DOI: 10.18632/aging.204245. View

Xiao Y, Tian F, Dai M, Wang W, Shao L, Zhang L . Are estrogen-related drugs new alternatives for the management of osteoarthritis?. Arthritis Res Ther. 2016; 18:151. PMC: 4924302. DOI: 10.1186/s13075-016-1045-7. View

Eriksen E, Shabestari M, Ghouri A, Conaghan P . Bisphosphonates as a treatment modality in osteoarthritis. Bone. 2020; 143:115352. DOI: 10.1016/j.bone.2020.115352. View

Zhang H, Wang H, Zeng C, Yan B, Ouyang J, Liu X . mTORC1 activation downregulates FGFR3 and PTH/PTHrP receptor in articular chondrocytes to initiate osteoarthritis. Osteoarthritis Cartilage. 2017; 25(6):952-963. DOI: 10.1016/j.joca.2016.12.024. View

Vaysbrot E, Osani M, Musetti M, McAlindon T, Bannuru R . Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2017; 26(2):154-164. DOI: 10.1016/j.joca.2017.11.013. View

Deeks E . Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2018; 35(2):163-173. DOI: 10.1007/s40266-018-0525-7. View

Ji M, Yu Q . Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2017; 1(1):9-13. PMC: 5643776. DOI: 10.1016/j.cdtm.2015.02.006. View

Chu L, Liu X, He Z, Han X, Yan M, Qu X . Articular Cartilage Degradation and Aberrant Subchondral Bone Remodeling in Patients with Osteoarthritis and Osteoporosis. J Bone Miner Res. 2019; 35(3):505-515. DOI: 10.1002/jbmr.3909. View

Qu Z, Yang F, Yan Y, Huang J, Zhao J, Hong J . A Mendelian randomization study on the role of serum parathyroid hormone and 25-hydroxyvitamin D in osteoarthritis. Osteoarthritis Cartilage. 2021; 29(9):1282-1290. DOI: 10.1016/j.joca.2021.04.015. View

10.

Karsdal M, Bay-Jensen A, Lories R, Abramson S, Spector T, Pastoureau P . The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?. Ann Rheum Dis. 2013; 73(2):336-48. DOI: 10.1136/annrheumdis-2013-204111. View

11.

Li G, Liu S, Xu H, Chen Y, Deng J, Xiong A . Potential effects of teriparatide (PTH (1-34)) on osteoarthritis: a systematic review. Arthritis Res Ther. 2023; 25(1):3. PMC: 9817404. DOI: 10.1186/s13075-022-02981-w. View

12.

Kawai T, Nishitani K, Okuzu Y, Goto K, Kuroda Y, Kuriyama S . Bisphosphonate use is associated with a decreased joint narrowing rate in the non-arthritic hip. Bone Joint Res. 2022; 11(11):826-834. PMC: 9680202. DOI: 10.1302/2046-3758.1111.BJR-2022-0155.R1. View

13.

Bei M, Tian F, Xiao Y, Cao X, Liu N, Zheng Z . Raloxifene retards cartilage degradation and improves subchondral bone micro-architecture in ovariectomized rats with patella baja-induced - patellofemoral joint osteoarthritis. Osteoarthritis Cartilage. 2019; 28(3):344-355. DOI: 10.1016/j.joca.2019.06.014. View

14.

Davis A, Smith T, Hing C, Sofat N . Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. PLoS One. 2013; 8(9):e72714. PMC: 3762823. DOI: 10.1371/journal.pone.0072714. View

15.

Huang G, Zhong Y, Li W, Liao W, Wu P . Causal Relationship Between Parathyroid Hormone and the Risk of Osteoarthritis: A Mendelian Randomization Study. Front Genet. 2021; 12:686939. PMC: 8352559. DOI: 10.3389/fgene.2021.686939. View

16.

Corciulo C, Scheffler J, Humeniuk P, Pons A, Stubelius A, von Mentzer U . Physiological levels of estradiol limit murine osteoarthritis progression. J Endocrinol. 2022; 255(2):39-51. PMC: 9513658. DOI: 10.1530/JOE-22-0032. View

17.

Tu K, Lie J, Wan C, Cameron M, Austel A, Nguyen J . Osteoporosis: A Review of Treatment Options. P T. 2018; 43(2):92-104. PMC: 5768298. View

18.

Pang K, Low N, Chin K . A Review on the Role of Denosumab in Fracture Prevention. Drug Des Devel Ther. 2020; 14:4029-4051. PMC: 7534845. DOI: 10.2147/DDDT.S270829. View

19.

Cheng C, Chen L, Chen K . Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int J Mol Sci. 2022; 23(3). PMC: 8836058. DOI: 10.3390/ijms23031376. View

20.

Zhang H, Bei M, Zheng Z, Liu N, Cao X, Xiao Y . Parathyroid Hormone (1-34) Attenuates Cartilage Degradation and Preserves Subchondral Bone Micro-architecture in Rats with Patella Baja-Induced-Patellofemoral Joint Osteoarthritis. Calcif Tissue Int. 2022; 111(1):87-95. DOI: 10.1007/s00223-022-00958-0. View